New platform coming soon — AI-Based Analysis with Human-Generated Insights

Stock Target Advisor

Daily Analyst Ratings

STA Research · Analyst intelligence

Daily analyst calls. One clear view.

Search published Canadian and U.S. analyst updates by company, firm and action.

November 18, 2026

283Published calls
14Upgrades
16Downgrades

Canada: 24 calls   U.S.: 259 calls  

283 calls shown

Company / TickerMarketAnalyst firmActionPrevious ratingRatingPrevious targetNew targetSource
AbbVieABBVU.S.Piper SandlerMaintains—Overweight—US$349.00Report
Details

AbbVie (ABBV) — Piper Sandler reiterated its Overweight rating with a price target of $349.00.

Report title
AbCellera BiologicsABCLU.S.Lake Street CapitalInitiates—Buy—US$19.00Report
Details

AbCellera Biologics (ABCL) — Lake Street Capital initiated coverage with a Buy rating and a price target of $19.00.

Report title
ACADIA PharmaceuticalsACADU.S.OppenheimerTarget Down—Market PerformUS$23.00US$21.00Report
Details

ACADIA Pharmaceuticals (ACAD) — Oppenheimer lowered its price target from $23.00 to $21.00, maintaining a Market Perform rating.

Report title
AdeiaADEAU.S.Rosenblatt SecuritiesMaintains—Buy—US$35.00Report
Details

Adeia (ADEA) — Rosenblatt Securities reiterated its Buy rating with a price target of $35.00.

Report title
Adherex TechnologiesFENCU.S.HC WainwrightTarget Up—BuyUS$16.00US$17.00Report
Details

Adherex Technologies (FENC) — HC Wainwright raised its price target from $16.00 to $17.00, maintaining a Buy rating.

Report title
AECOMACMU.S.BarclaysTarget Up—Equal WeightUS$73.00US$90.00Report
Details

AECOM (ACM) — Barclays raised its price target from $73.00 to $90.00, maintaining an Equal Weight rating.

Report title
AECOMACMU.S.KeyCorpTarget Up—OverweightUS$78.00US$97.00Report
Details

AECOM (ACM) — KeyCorp raised its price target from $78.00 to $97.00, maintaining an Overweight rating.

Report title
Affiliated Managers GroupAMGU.S.TD CowenMaintains—Buy—US$583.00Report
Details

Affiliated Managers Group (AMG) — TD Cowen reiterated its Buy rating with a price target of $583.00.

Report title
Aldebaran Resources Inc.ALDE:CACanadaNational BankMaintains—Outperform—C$5.00Report
Details

Aldebaran Resources Inc. (ALDE:CA) — National Bank maintained an Outperform rating with a price target of C$5.00.

Report title
Alnylam PharmaceuticalsALNYU.S.JPMorgan Chase & Co.Maintains———US$254.00Report
Details

Alnylam Pharmaceuticals (ALNY) — JPMorgan Chase & Co. reiterated its price target with a price target of $254.00.

Report title
Alnylam PharmaceuticalsALNYU.S.Rodman & RenshawDowngrade—Neutral——Report
Details

Alnylam Pharmaceuticals (ALNY) — Rodman & Renshaw downgraded the stock to Neutral.

Report title
Amer SportsASU.S.Cantor FitzgeraldTarget Up—OverweightUS$46.00US$47.00Report
Details

Amer Sports (AS) — Cantor Fitzgerald raised its price target from $46.00 to $47.00, maintaining an Overweight rating.

Report title
Amer SportsASU.S.UBS GroupTarget Down—BuyUS$62.00US$56.00Report
Details

Amer Sports (AS) — UBS Group lowered its price target from $62.00 to $56.00, maintaining a Buy rating.

Report title
American Axle & ManufacturingDCHU.S.Morgan StanleyTarget Down—Equal WeightUS$7.00US$6.00Report
Details

American Axle & Manufacturing (DCH) — Morgan Stanley lowered its price target from $7.00 to $6.00, maintaining an Equal Weight rating.

Report title
American Axle & ManufacturingDCHU.S.TD CowenMaintains—Buy—US$10.00Report
Details

American Axle & Manufacturing (DCH) — TD Cowen reiterated its Buy rating with a price target of $10.00.

Report title
Antero ResourcesARU.S.Morgan StanleyTarget Up—OverweightUS$51.00US$52.00Report
Details

Antero Resources (AR) — Morgan Stanley raised its price target from $51.00 to $52.00, maintaining an Overweight rating.

Report title
APA CorporationAPAU.S.Morgan StanleyTarget Up—UnderweightUS$43.00US$44.00Report
Details

APA Corporation (APA) — Morgan Stanley raised its price target from $43.00 to $44.00, maintaining an Underweight rating.

Report title
AppLovinAPPU.S.JPMorgan Chase & Co.Maintains———US$400.00Report
Details

AppLovin (APP) — JPMorgan Chase & Co. reiterated its price target with a price target of $400.00.

Report title
Atrium Mortgage Investment CorporationAI:CACanadaFundamental ResearchMaintains—Buy—C$12.49Report
Details

Atrium Mortgage Investment Corporation (AI:CA) — Fundamental Research maintained a Buy rating with a price target of C$12.49.

Report title
BaiduBIDUU.S.BarclaysTarget Down—Equal WeightUS$80.00US$72.00Report
Details

Baidu (BIDU) — Barclays lowered its price target from $80.00 to $72.00, maintaining an Equal Weight rating.

Report title
BaiduBIDUU.S.Stifel NicolausMaintains———US$83.00Report
Details

Baidu (BIDU) — Stifel Nicolaus reiterated its price target with a price target of $83.00.

Report title
BaiduBIDUU.S.SusquehannaTarget Down—NeutralUS$105.00US$75.00Report
Details

Baidu (BIDU) — Susquehanna lowered its price target from $105.00 to $75.00, maintaining a Neutral rating.

Report title
Bally'sBALYU.S.Truist FinancialTarget Down—HoldUS$10.00US$9.00Report
Details

Bally's (BALY) — Truist Financial lowered its price target from $10.00 to $9.00, maintaining a Hold rating.

Report title
BILL Holdings, Inc.BILLU.S.BMO Capital MarketsTarget Up—Market PerformUS$56.00US$68.00Report
Details

BILL Holdings, Inc. (BILL) — BMO Capital Markets raised its price target from $56.00 to $68.00, maintaining a Market Perform rating.

Report title
BiogenBIIBU.S.Needham & Company LLCMaintains—Buy——Report
Details

Biogen (BIIB) — Needham & Company LLC reiterated its Buy rating.

Report title
Bitdeer Technologies GroupBTDRU.S.StoneXTarget Down—BuyUS$22.00US$15.00Report
Details

Bitdeer Technologies Group (BTDR) — StoneX lowered its price target from $22.00 to $15.00, maintaining a Buy rating.

Report title
Black Diamond Group Ltd.BDI:CACanadaCanaccord GenuityMaintains—Buy—C$26.00Report
Details

Black Diamond Group Ltd. (BDI:CA) — Canaccord Genuity maintained a Buy rating with a price target of C$26.00.

Report title
BlackLineBLU.S.BMO Capital MarketsTarget Down—Market PerformUS$32.00US$30.00Report
Details

BlackLine (BL) — BMO Capital Markets lowered its price target from $32.00 to $30.00, maintaining a Market Perform rating.

Report title
Bridger Aerospace GroupBAERU.S.Canaccord Genuity GroupDowngradeBuyHold—US$1.00Report
Details

Bridger Aerospace Group (BAER) — Canaccord Genuity Group downgraded the stock from Buy to Hold, with a price target of $1.00.

Report title
Bridger Aerospace GroupBAERU.S.Stifel NicolausDowngradeBuyHold—US$0.25Report
Details

Bridger Aerospace Group (BAER) — Stifel Nicolaus downgraded the stock from Buy to Hold, with a price target of $0.25.

Report title
BrightSpring Health ServicesBTSGU.S.BMO Capital MarketsTarget Up—OutperformUS$80.00US$84.00Report
Details

BrightSpring Health Services (BTSG) — BMO Capital Markets raised its price target from $80.00 to $84.00, maintaining an Outperform rating.

Report title
BrookfieldBNU.S.Morgan StanleyTarget Down—OverweightUS$54.00US$52.00Report
Details

Brookfield (BN) — Morgan Stanley lowered its price target from $54.00 to $52.00, maintaining an Overweight rating.

Report title
Brookfield Asset ManagementBAMU.S.Morgan StanleyTarget Up—Equal WeightUS$54.00US$57.00Report
Details

Brookfield Asset Management (BAM) — Morgan Stanley raised its price target from $54.00 to $57.00, maintaining an Equal Weight rating.

Report title
Builders FirstSourceBLDRU.S.Royal Bank Of CanadaMaintains—Sector Perform—US$56.00Report
Details

Builders FirstSource (BLDR) — Royal Bank Of Canada reiterated its Sector Perform rating with a price target of $56.00.

Report title
BWX TechnologiesBWXTU.S.TD CowenTarget Down—BuyUS$230.00US$180.00Report
Details

BWX Technologies (BWXT) — TD Cowen lowered its price target from $230.00 to $180.00, maintaining a Buy rating.

Report title
CalumetCLMTU.S.TD CowenTarget Down—HoldUS$40.00US$37.00Report
Details

Calumet (CLMT) — TD Cowen lowered its price target from $40.00 to $37.00, maintaining a Hold rating.

Report title
CamtekCAMTU.S.Northland CapitalUpgradeMarket PerformOutperform—US$130.00Report
Details

Camtek (CAMT) — Northland Capital upgraded the stock from Market Perform to Outperform, with a price target of $130.

Report title
CamtekCAMTU.S.Northland SecuritiesUpgradeMarket PerformOutperform—US$130.00Report
Details

Camtek (CAMT) — Northland Securities upgraded the stock from Market Perform to Outperform, with a price target of $130.00.

Report title
Cardinal HealthCAHU.S.BarclaysTarget Up—OverweightUS$275.00US$320.00Report
Details

Cardinal Health (CAH) — Barclays raised its price target from $275.00 to $320.00, maintaining an Overweight rating.

Report title
CaterpillarCATU.S.DA DavidsonMaintains———US$685.00Report
Details

Caterpillar (CAT) — DA Davidson reiterated its price target with a price target of $685.00.

Report title
CelsiusCELHU.S.Wolfe ResearchInitiates—Outperform—US$39.00Report
Details

Celsius (CELH) — Wolfe Research initiated coverage with a Outperform rating and a price target of $39.00.

Report title
CencoraCORU.S.BarclaysTarget Up—OverweightUS$350.00US$415.00Report
Details

Cencora (COR) — Barclays raised its price target from $350.00 to $415.00, maintaining an Overweight rating.

Report title
CevaCEVAU.S.Rosenblatt SecuritiesMaintains—Buy—US$49.00Report
Details

Ceva (CEVA) — Rosenblatt Securities reiterated its Buy rating with a price target of $49.00.

Report title
CG OncologyCGONU.S.Morgan StanleyTarget Up—OverweightUS$102.00US$117.00Report
Details

CG Oncology (CGON) — Morgan Stanley raised its price target from $102.00 to $117.00, maintaining an Overweight rating.

Report title
Charles SchwabSCHWU.S.Raymond JamesUpgradeOutperformStrong Buy—US$135.00Report
Details

Charles Schwab (SCHW) — Raymond James upgraded the stock from Outperform to Strong Buy, with a price target of $135.

Report title
Charles SchwabSCHWU.S.Raymond James FinancialUpgradeOutperformStrong-Buy—US$135.00Report
Details

Charles Schwab (SCHW) — Raymond James Financial upgraded the stock from Outperform to Strong-Buy, with a price target of $135.00.

Report title
Chemtrade Logistics Income FundCHE.UN:CACanadaScotiabankMaintains—Sector Perform—C$19.00Report
Details

Chemtrade Logistics Income Fund (CHE.UN:CA) — Scotiabank maintained a Sector Perform rating with a price target of C$19.00.

Report title
Chime FinancialCHYMU.S.B. Riley FinancialTarget Up—BuyUS$45.00US$55.00Report
Details

Chime Financial (CHYM) — B. Riley Financial reiterated its Buy rating with its price target from $45.00 to $55.00.

Report title
Chord EnergyCHRDU.S.Morgan StanleyTarget Up—OverweightUS$178.00US$183.00Report
Details

Chord Energy (CHRD) — Morgan Stanley raised its price target from $178.00 to $183.00, maintaining an Overweight rating.

Report title
Chord EnergyCHRDU.S.Truist FinancialMaintains———US$197.00Report
Details

Chord Energy (CHRD) — Truist Financial reiterated its price target with a price target of $197.00.

Report title
Church & DwightCHDU.S.Bank of AmericaTarget Up—BuyUS$115.00US$125.00Report
Details

Church & Dwight (CHD) — Bank of America raised its price target from $115.00 to $125.00, maintaining a Buy rating.

Report title
Cleveland-CliffsCLFU.S.Wells Fargo & CompanyTarget Up—OverweightUS$17.00US$18.00Report
Details

Cleveland-Cliffs (CLF) — Wells Fargo & Company raised its price target from $17.00 to $18.00, maintaining an Overweight rating.

Report title
Climb BioCLYMU.S.Royal Bank Of CanadaMaintains—Outperform—US$23.00Report
Details

Climb Bio (CLYM) — Royal Bank Of Canada reiterated its Outperform rating with a price target of $23.00.

Report title
CNX ResourcesCNXU.S.Morgan StanleyUpgradeUnderweightEqual WeightUS$34.00US$36.00Report
Details

CNX Resources (CNX) — Morgan Stanley upgraded the stock from Underweight to Equal Weight and changed its price target from $34.00 to $36.00.

Report title
Coca-ColaKOU.S.Wolfe ResearchInitiates—Outperform——Report
Details

Coca-Cola (KO) — Wolfe Research initiated coverage with a Outperform rating.

Report title
Commercial MetalsCMCU.S.Wells Fargo & CompanyTarget Down—Equal WeightUS$70.00US$63.00Report
Details

Commercial Metals (CMC) — Wells Fargo & Company lowered its price target from $70.00 to $63.00, maintaining an Equal Weight rating.

Report title
Comstock ResourcesCRKU.S.BarclaysDowngrade—Underweight——Report
Details

Comstock Resources (CRK) — Barclays downgraded the stock to Underweight.

Report title
Comstock ResourcesCRKU.S.Morgan StanleyDowngradeEqual WeightUnderweight—US$13.00Report
Details

Comstock Resources (CRK) — Morgan Stanley downgraded the stock from Equal Weight to Underweight, with a price target of $13.00.

Report title
ConocoPhillipsCOPU.S.Morgan StanleyTarget Up—OverweightUS$159.00US$160.00Report
Details

ConocoPhillips (COP) — Morgan Stanley raised its price target from $159.00 to $160.00, maintaining an Overweight rating.

Report title
CredicorpBAPU.S.UBS GroupTarget Down—BuyUS$473.00US$458.00Report
Details

Credicorp (BAP) — UBS Group lowered its price target from $473.00 to $458.00, maintaining a Buy rating.

Report title
Crombie REITCRR.UN:CACanadaCIBCMaintains—Outperform—C$18.00Report
Details

Crombie REIT (CRR.UN:CA) — CIBC maintained an Outperform rating with a price target of C$18.00.

Report title
Crombie REITCRR.UN:CACanadaTD SecuritiesResumes—Buy—C$18.00Report
Details

Crombie REIT (CRR.UN:CA) — TD Securities resumed coverage with a Buy rating and a price target of C$18.00.

Report title
Cue BiopharmaCUEU.S.B. Riley FinancialMaintains—Buy——Report
Details

Cue Biopharma (CUE) — B. Riley Financial reiterated its Buy rating.

Report title
Deere & CompanyDEU.S.OppenheimerMaintains—Outperform——Report
Details

Deere & Company (DE) — Oppenheimer reiterated its Outperform rating.

Report title
Devon EnergyDVNU.S.Morgan StanleyTarget Up—OverweightUS$64.00US$65.00Report
Details

Devon Energy (DVN) — Morgan Stanley raised its price target from $64.00 to $65.00, maintaining an Overweight rating.

Report title
Diamondback EnergyFANGU.S.Royal Bank Of CanadaMaintains—Outperform—US$240.00Report
Details

Diamondback Energy (FANG) — Royal Bank Of Canada reiterated its Outperform rating with a price target of $240.00.

Report title
Disc MedicineIRONU.S.Morgan StanleyTarget Up—OverweightUS$92.00US$104.00Report
Details

Disc Medicine (IRON) — Morgan Stanley raised its price target from $92.00 to $104.00, maintaining an Overweight rating.

Report title
DLocalDLOU.S.Truist FinancialTarget Down—BuyUS$17.00US$16.00Report
Details

DLocal (DLO) — Truist Financial lowered its price target from $17.00 to $16.00, maintaining a Buy rating.

Report title
DocusignDOCUU.S.BTIG ResearchTarget Up—BuyUS$75.00US$90.00Report
Details

Docusign (DOCU) — BTIG Research raised its price target from $75.00 to $90.00, maintaining a Buy rating.

Report title
Dollarama Inc.DOL:CACanadaTD SecuritiesTarget Up—BuyC$217.00C$250.00Report
Details

Dollarama Inc. (DOL:CA) — TD Securities raised its price target from C$217.00 to C$250.00, maintaining a Buy rating and identifying Dollarama as one of its preferred investment ideas for 2027.

Report title
Duos Technologies GroupDUOTU.S.Chardan CapitalTarget Down—NeutralUS$9.50US$5.50Report
Details

Duos Technologies Group (DUOT) — Chardan Capital lowered its price target from $9.50 to $5.50, maintaining a Neutral rating.

Report title
Dutch BrosBROSU.S.GuggenheimTarget Down—BuyUS$76.00US$62.00Report
Details

Dutch Bros (BROS) — Guggenheim lowered its price target from $76.00 to $62.00, maintaining a Buy rating.

Report title
EatonETNU.S.Erste Group BankDowngradeBuyHold——Report
Details

Eaton (ETN) — Erste Group Bank downgraded the stock from Buy to Hold.

Report title
EcolabECLU.S.OppenheimerTarget Up—OutperformUS$320.00US$331.00Report
Details

Ecolab (ECL) — Oppenheimer raised its price target from $320.00 to $331.00, maintaining an Outperform rating.

Report title
EcolabECLU.S.Robert W. BairdTarget Up—OutperformUS$317.00US$324.00Report
Details

Ecolab (ECL) — Robert W. Baird raised its price target from $317.00 to $324.00, maintaining an Outperform rating.

Report title
EcolabECLU.S.Stifel NicolausTarget Up—BuyUS$337.00US$356.00Report
Details

Ecolab (ECL) — Stifel Nicolaus raised its price target from $337.00 to $356.00, maintaining a Buy rating.

Report title
Eikon TherapeuticsEIKNU.S.Morgan StanleyTarget Down—Overweight—US$30.00Report
Details

Eikon Therapeutics (EIKN) — Morgan Stanley lowered its price target to $30.00, maintaining an Overweight rating.

Report title
Elbit SystemsESLTU.S.JPMorgan Chase & Co.Target Up—NeutralUS$885.00US$900.00Report
Details

Elbit Systems (ESLT) — JPMorgan Chase & Co. raised its price target from $885.00 to $900.00, maintaining a Neutral rating.

Report title
Elevance HealthELVU.S.ArgusUpgradeHoldBuy—US$510.00Report
Details

Elevance Health (ELV) — Argus upgraded the stock from Hold to Buy, with a price target of $510.00.

Report title
EnergizerENRU.S.JPMorgan Chase & Co.Target Up—NeutralUS$22.00US$25.00Report
Details

Energizer (ENR) — JPMorgan Chase & Co. raised its price target from $22.00 to $25.00, maintaining a Neutral rating.

Report title
EnergizerENRU.S.Morgan StanleyTarget Up—Equal WeightUS$21.00US$27.00Report
Details

Energizer (ENR) — Morgan Stanley raised its price target from $21.00 to $27.00, maintaining an Equal Weight rating.

Report title
EnergizerENRU.S.UBS GroupTarget Up—NeutralUS$22.00US$28.00Report
Details

Energizer (ENR) — UBS Group raised its price target from $22.00 to $28.00, maintaining a Neutral rating.

Report title
EnovixENVXU.S.Bank of AmericaDowngradeNeutralUnderperformUS$5.00US$1.00Report
Details

Enovix (ENVX) — Bank of America downgraded the stock from Neutral to Underperform and changed its price target from $5.00 to $1.00.

Report title
Entrada TherapeuticsTRDAU.S.GuggenheimTarget Down—BuyUS$17.00US$13.00Report
Details

Entrada Therapeutics (TRDA) — Guggenheim lowered its price target from $17.00 to $13.00, maintaining a Buy rating.

Report title
EOG ResourcesEOGU.S.Morgan StanleyTarget Up—Equal WeightUS$163.00US$167.00Report
Details

EOG Resources (EOG) — Morgan Stanley raised its price target from $163.00 to $167.00, maintaining an Equal Weight rating.

Report title
EQT CorporationEQTU.S.Morgan StanleyTarget Down—OverweightUS$67.00US$66.00Report
Details

EQT Corporation (EQT) — Morgan Stanley lowered its price target from $67.00 to $66.00, maintaining an Overweight rating.

Report title
Expand EnergyEXEU.S.Morgan StanleyTarget Down—OverweightUS$123.00US$120.00Report
Details

Expand Energy (EXE) — Morgan Stanley lowered its price target from $123.00 to $120.00, maintaining an Overweight rating.

Report title
ExxonMobilXOMU.S.Erste Group BankUpgradeHoldBuy——Report
Details

ExxonMobil (XOM) — Erste Group Bank upgraded the stock from Hold to Buy.

Report title
FergusonFERGU.S.Bank of AmericaTarget Up—BuyUS$315.00US$320.00Report
Details

Ferguson (FERG) — Bank of America raised its price target from $315.00 to $320.00, maintaining a Buy rating.

Report title
Franco-Nevada CorporationFNV:CACanadaCIBCMaintains—Outperform—C$480.00Report
Details

Franco-Nevada Corporation (FNV:CA) — CIBC maintained an Outperform rating with a price target of C$480.00.

Report title
Freeport-McMoRanFCXU.S.Erste Group BankDowngradeBuyHold——Report
Details

Freeport-McMoRan (FCX) — Erste Group Bank downgraded the stock from Buy to Hold.

Report title
fuboTVFUBOU.S.Barrington ResearchTarget Down—OutperformUS$16.00US$12.00Report
Details

fuboTV (FUBO) — Barrington Research lowered its price target from $16.00 to $12.00, maintaining an Outperform rating.

Report title
fuboTVFUBOU.S.BTIG ResearchMaintains—Neutral——Report
Details

fuboTV (FUBO) — BTIG Research reiterated its Neutral rating.

Report title
FutuFUTUU.S.JPMorgan Chase & Co.Target Down—NeutralUS$122.00US$103.00Report
Details

Futu (FUTU) — JPMorgan Chase & Co. lowered its price target from $122.00 to $103.00, maintaining a Neutral rating.

Report title
GE HealthCare TechnologiesGEHCU.S.BTIG ResearchTarget Up—BuyUS$83.00US$91.00Report
Details

GE HealthCare Technologies (GEHC) — BTIG Research raised its price target from $83.00 to $91.00, maintaining a Buy rating.

Report title
GE VernovaGEVU.S.Erste Group BankDowngradeBuyHold——Report
Details

GE Vernova (GEV) — Erste Group Bank downgraded the stock from Buy to Hold.

Report title
GeneDxWGSU.S.BTIG ResearchMaintains—Buy—US$85.00Report
Details

GeneDx (WGS) — BTIG Research reiterated its Buy rating with a price target of $85.00.

Report title
General Fusion GroupGFUZU.S.WedbushMaintains—Neutral—US$7.00Report
Details

General Fusion Group (GFUZ) — Wedbush reiterated its Neutral rating with a price target of $7.00.

Report title
Generate BiomedicinesGENBU.S.Morgan StanleyTarget Down—OverweightUS$22.00US$21.00Report
Details

Generate Biomedicines (GENB) — Morgan Stanley lowered its price target from $22.00 to $21.00, maintaining an Overweight rating.

Report title
Geo GroupGEOU.S.JonesTradingMaintains—Buy—US$42.75Report
Details

Geo Group (GEO) — JonesTrading reiterated its Buy rating with a price target of $42.75.

Report title
GH ResearchGHRSU.S.GuggenheimTarget Up—BuyUS$40.00US$46.00Report
Details

GH Research (GHRS) — Guggenheim raised its price target from $40.00 to $46.00, maintaining a Buy rating.

Report title
Granite Point Mortgage TrustGPMTU.S.UBS GroupTarget Down—Neutral—US$3.00Report
Details

Granite Point Mortgage Trust (GPMT) — UBS Group lowered its price target to $3.00, maintaining a Neutral rating.

Report title
Gray MediaGTNU.S.GuggenheimTarget Up—BuyUS$7.00US$8.00Report
Details

Gray Media (GTN) — Guggenheim raised its price target from $7.00 to $8.00, maintaining a Buy rating.

Report title
Greenwich LifeSciencesGLSIU.S.HC WainwrightTarget Up—BuyUS$69.00US$70.00Report
Details

Greenwich LifeSciences (GLSI) — HC Wainwright raised its price target from $69.00 to $70.00, maintaining a Buy rating.

Report title
Groupe Dynamite Inc.GRGD:CACanadaScotiabankMaintains—Sector Outperform—C$75.00Report
Details

Groupe Dynamite Inc. (GRGD:CA) — Scotiabank maintained a Sector Outperform rating with a price target of C$75.00.

Report title
Guardant HealthGHU.S.TD CowenMaintains—Buy——Report
Details

Guardant Health (GH) — TD Cowen reiterated its Buy rating.

Report title
HA Sustainable Infrastructure CapitalHASIU.S.Jefferies Financial GroupMaintains—Buy—US$46.00Report
Details

HA Sustainable Infrastructure Capital (HASI) — Jefferies Financial Group reiterated its Buy rating with a price target of $46.00.

Report title
HCA HealthcareHCAU.S.JPMorgan Chase & Co.Target Up—NeutralUS$425.00US$475.00Report
Details

HCA Healthcare (HCA) — JPMorgan Chase & Co. raised its price target from $425.00 to $475.00, maintaining a Neutral rating.

Report title
HersheyHSYU.S.TD CowenMaintains—Hold—US$173.00Report
Details

Hershey (HSY) — TD Cowen reiterated its Hold rating with a price target of $173.00.

Report title
Home DepotHDU.S.DA DavidsonTarget Up—BuyUS$377.00US$390.00Report
Details

Home Depot (HD) — DA Davidson raised its price target from $377.00 to $390.00, maintaining a Buy rating.

Report title
Home DepotHDU.S.JPMorgan Chase & Co.Maintains———US$390.00Report
Details

Home Depot (HD) — JPMorgan Chase & Co. reiterated its price target with a price target of $390.00.

Report title
Home DepotHDU.S.MizuhoTarget Down—OutperformUS$390.00US$385.00Report
Details

Home Depot (HD) — Mizuho lowered its price target from $390.00 to $385.00, maintaining an Outperform rating.

Report title
Home DepotHDU.S.Royal Bank Of CanadaTarget Down—Sector PerformUS$342.00US$334.00Report
Details

Home Depot (HD) — Royal Bank Of Canada lowered its price target from $342.00 to $334.00, maintaining a Sector Perform rating.

Report title
Home DepotHDU.S.Sanford C. BernsteinTarget Up—Market PerformUS$357.00US$360.00Report
Details

Home Depot (HD) — Sanford C. Bernstein raised its price target from $357.00 to $360.00, maintaining a Market Perform rating.

Report title
Home DepotHDU.S.Truist FinancialTarget Up—BuyUS$373.00US$376.00Report
Details

Home Depot (HD) — Truist Financial raised its price target from $373.00 to $376.00, maintaining a Buy rating.

Report title
Home DepotHDU.S.UBS GroupTarget Down—BuyUS$420.00US$417.00Report
Details

Home Depot (HD) — UBS Group lowered its price target from $420.00 to $417.00, maintaining a Buy rating.

Report title
Hornbeck Offshore ServicesHOSU.S.Pickering Energy PartnersUpgradeNeutralOutperform——Report
Details

Hornbeck Offshore Services (HOS) — Pickering Energy Partners upgraded the stock from Neutral to Outperform.

Report title
HyperfineHYPRU.S.B. Riley FinancialTarget Down—BuyUS$1.60US$1.40Report
Details

Hyperfine (HYPR) — B. Riley Financial reiterated its Buy rating with its price target from $1.60 to $1.40.

Report title
Immix BiopharmaIMMXU.S.MizuhoTarget Down—OutperformUS$23.00US$22.00Report
Details

Immix Biopharma (IMMX) — Mizuho lowered its price target from $23.00 to $22.00, maintaining an Outperform rating.

Report title
Immix BiopharmaIMMXU.S.Morgan StanleyTarget Up—OverweightUS$20.00US$21.00Report
Details

Immix Biopharma (IMMX) — Morgan Stanley raised its price target from $20.00 to $21.00, maintaining an Overweight rating.

Report title
ImmunicIMUXU.S.HC WainwrightMaintains—Buy——Report
Details

Immunic (IMUX) — HC Wainwright reiterated its Buy rating.

Report title
Imperial Oil Ltd.IMO:CACanadaBMOTarget Up—UnderperformC$133.00C$138.00Report
Details

Imperial Oil Ltd. (IMO:CA) — BMO raised its price target from C$133.00 to C$138.00, maintaining an Underperform rating.

Report title
InnovivaINVAU.S.Piper SandlerInitiates—Overweight—US$29.00Report
Details

Innoviva (INVA) — Piper Sandler initiated coverage with a Overweight rating and a price target of $29.00.

Report title
InsuletPODDU.S.Stifel NicolausDowngradeBuyHoldUS$180.00US$165.00Report
Details

Insulet (PODD) — Stifel Nicolaus downgraded the stock from Buy to Hold and changed its price target from $180.00 to $165.00.

Report title
Intuitive SurgicalISRGU.S.BTIG ResearchTarget Up—BuyUS$454.00US$513.00Report
Details

Intuitive Surgical (ISRG) — BTIG Research raised its price target from $454.00 to $513.00, maintaining a Buy rating.

Report title
Ionis PharmaceuticalsIONSU.S.GuggenheimTarget Down—BuyUS$80.00US$65.00Report
Details

Ionis Pharmaceuticals (IONS) — Guggenheim lowered its price target from $80.00 to $65.00, maintaining a Buy rating.

Report title
ITT Inc.ITTU.S.TD CowenTarget Up—BuyUS$250.00US$260.00Report
Details

ITT Inc. (ITT) — TD Cowen raised its price target from $250.00 to $260.00, maintaining a Buy rating.

Report title
J. M. SmuckerSJMU.S.UBS GroupTarget Up—BuyUS$149.00US$153.00Report
Details

J. M. Smucker (SJM) — UBS Group raised its price target from $149.00 to $153.00, maintaining a Buy rating.

Report title
Jamieson Wellness Inc.JWEL:CACanadaTD SecuritiesMaintains—Sell—C$45.75Report
Details

Jamieson Wellness Inc. (JWEL:CA) — TD Securities maintained a Sell rating with a price target of C$45.75.

Report title
JD.comJDU.S.BarclaysTarget Down—OverweightUS$38.00US$33.00Report
Details

JD.com (JD) — Barclays lowered its price target from $38.00 to $33.00, maintaining an Overweight rating.

Report title
JD.comJDU.S.MizuhoTarget Down—OutperformUS$37.00US$34.00Report
Details

JD.com (JD) — Mizuho lowered its price target from $37.00 to $34.00, maintaining an Outperform rating.

Report title
JD.comJDU.S.Sanford C. BernsteinTarget Down—OutperformUS$40.00US$38.00Report
Details

JD.com (JD) — Sanford C. Bernstein lowered its price target from $40.00 to $38.00, maintaining an Outperform rating.

Report title
JD.comJDU.S.StoneXMaintains———US$42.00Report
Details

JD.com (JD) — StoneX reiterated its price target with a price target of $42.00.

Report title
Kelt Exploration Ltd.KEL:CACanadaScotiabankTarget Up—Sector OutperformC$13.50C$14.00Report
Details

Kelt Exploration Ltd. (KEL:CA) — Scotiabank raised its price target from C$13.50 to C$14.00, maintaining a Sector Outperform rating.

Report title
Keurig Dr PepperKDPU.S.Wolfe ResearchInitiates—Outperform—US$42.00Report
Details

Keurig Dr Pepper (KDP) — Wolfe Research initiated coverage with a Outperform rating and a price target of $42.00.

Report title
Klarna GroupKLARU.S.Bank of AmericaTarget Up—BuyUS$19.00US$20.00Report
Details

Klarna Group (KLAR) — Bank of America raised its price target from $19.00 to $20.00, maintaining a Buy rating.

Report title
Klarna GroupKLARU.S.BMO Capital MarketsTarget Down—Market PerformUS$14.00US$13.00Report
Details

Klarna Group (KLAR) — BMO Capital Markets lowered its price target from $14.00 to $13.00, maintaining a Market Perform rating.

Report title
Klarna GroupKLARU.S.JPMorgan Chase & Co.Target Down—NeutralUS$18.00US$17.00Report
Details

Klarna Group (KLAR) — JPMorgan Chase & Co. lowered its price target from $18.00 to $17.00, maintaining a Neutral rating.

Report title
Klarna GroupKLARU.S.Morgan StanleyTarget Down—Equal WeightUS$17.00US$14.00Report
Details

Klarna Group (KLAR) — Morgan Stanley lowered its price target from $17.00 to $14.00, maintaining an Equal Weight rating.

Report title
Lantern PharmaLTRNU.S.Rodman & RenshawDowngradeBuyNeutral——Report
Details

Lantern Pharma (LTRN) — Rodman & Renshaw downgraded the stock from Buy to Neutral.

Report title
Liberty GlobalLBTYAU.S.CitigroupResumes—Neutral—US$11.00Report
Details

Liberty Global (LBTYA) — Citigroup resumed coverage with a Neutral rating and a price target of $11.00.

Report title
LifeMDLFMDU.S.HC WainwrightTarget Down—BuyUS$9.00US$6.00Report
Details

LifeMD (LFMD) — HC Wainwright lowered its price target from $9.00 to $6.00, maintaining a Buy rating.

Report title
Liftoff MobileLFTOU.S.UBS GroupTarget Up—BuyUS$25.00US$35.00Report
Details

Liftoff Mobile (LFTO) — UBS Group raised its price target from $25.00 to $35.00, maintaining a Buy rating.

Report title
Lodestar Metals Corp.LSTR:CACanadaFundamental ResearchMaintains—Buy—C$0.33Report
Details

Lodestar Metals Corp. (LSTR:CA) — Fundamental Research maintained a Buy rating with a price target of C$0.33.

Report title
Lowe's CompaniesLOWU.S.TD CowenMaintains—Hold—US$235.00Report
Details

Lowe's Companies (LOW) — TD Cowen reiterated its Hold rating with a price target of $235.00.

Report title
Lowe's CompaniesLOWU.S.Truist FinancialMaintains———US$254.00Report
Details

Lowe's Companies (LOW) — Truist Financial reiterated its price target with a price target of $254.00.

Report title
Lumexa ImagingLMRIU.S.Wells Fargo & CompanyTarget Up—OverweightUS$19.00US$21.00Report
Details

Lumexa Imaging (LMRI) — Wells Fargo & Company raised its price target from $19.00 to $21.00, maintaining an Overweight rating.

Report title
LuxExperience B.V.LUXEU.S.B. Riley FinancialTarget Up—BuyUS$13.00US$14.00Report
Details

LuxExperience B.V. (LUXE) — B. Riley Financial reiterated its Buy rating with its price target from $13.00 to $14.00.

Report title
LuxExperience B.V.LUXEU.S.TD CowenTarget Up—BuyUS$12.00US$13.50Report
Details

LuxExperience B.V. (LUXE) — TD Cowen raised its price target from $12.00 to $13.50, maintaining a Buy rating.

Report title
Manhattan AssociatesMANHU.S.JPMorgan Chase & Co.Initiates—Overweight—US$308.00Report
Details

Manhattan Associates (MANH) — JPMorgan Chase & Co. initiated coverage with a Overweight rating and a price target of $308.00.

Report title
MARA HoldingsMARAU.S.BTIG ResearchMaintains—Buy—US$27.00Report
Details

MARA Holdings (MARA) — BTIG Research reiterated its Buy rating with a price target of $27.00.

Report title
Matador ResourcesMTDRU.S.Morgan StanleyTarget Up—Equal WeightUS$69.00US$70.00Report
Details

Matador Resources (MTDR) — Morgan Stanley raised its price target from $69.00 to $70.00, maintaining an Equal Weight rating.

Report title
McDonald'sMCDU.S.KeyCorpMaintains—Overweight——Report
Details

McDonald's (MCD) — KeyCorp reiterated its Overweight rating.

Report title
McKessonMCKU.S.BarclaysTarget Up—OverweightUS$1,000.00US$1,235.00Report
Details

McKesson (MCK) — Barclays raised its price target from $1,000.00 to $1,235.00, maintaining an Overweight rating.

Report title
MDU Resources GroupMDUU.S.TD CowenMaintains—Hold—US$22.00Report
Details

MDU Resources Group (MDU) — TD Cowen reiterated its Hold rating with a price target of $22.00.

Report title
Metro Inc.MRU:CACanadaCIBCMaintains—Outperform—C$112.00Report
Details

Metro Inc. (MRU:CA) — CIBC maintained an Outperform rating with a price target of C$112.00.

Report title
Metro Inc.MRU:CACanadaTD SecuritiesMaintains—Buy—C$108.00Report
Details

Metro Inc. (MRU:CA) — TD Securities maintained a Buy rating with a price target of C$108.00.

Report title
Micron TechnologyMUU.S.Royal Bank Of CanadaMaintains—Outperform—US$1,500.00Report
Details

Micron Technology (MU) — Royal Bank Of Canada reiterated its Outperform rating with a price target of $1,500.00.

Report title
MicrosoftMSFTU.S.JPMorgan Chase & Co.Maintains———US$625.00Report
Details

Microsoft (MSFT) — JPMorgan Chase & Co. reiterated its price target with a price target of $625.00.

Report title
MicrosoftMSFTU.S.MizuhoMaintains———US$625.00Report
Details

Microsoft (MSFT) — Mizuho reiterated its price target with a price target of $625.00.

Report title
MicrosoftMSFTU.S.OppenheimerMaintains—Outperform——Report
Details

Microsoft (MSFT) — Oppenheimer reiterated its Outperform rating.

Report title
MicrosoftMSFTU.S.Piper SandlerMaintains—Overweight——Report
Details

Microsoft (MSFT) — Piper Sandler reiterated its Overweight rating.

Report title
MicrosoftMSFTU.S.TD CowenMaintains—Buy—US$650.00Report
Details

Microsoft (MSFT) — TD Cowen reiterated its Buy rating with a price target of $650.00.

Report title
MicrosoftMSFTU.S.UBS GroupMaintains—Overweight——Report
Details

Microsoft (MSFT) — UBS Group reiterated its Overweight rating.

Report title
MiddlebyMIDDU.S.OppenheimerMaintains—Outperform——Report
Details

Middleby (MIDD) — Oppenheimer reiterated its Outperform rating.

Report title
Midera Food ProcessingMFPU.S.Robert W. BairdTarget Up—NeutralUS$40.00US$43.00Report
Details

Midera Food Processing (MFP) — Robert W. Baird raised its price target from $40.00 to $43.00, maintaining a Neutral rating.

Report title
Millicom International CellularTIGOU.S.JPMorgan Chase & Co.UpgradeNeutralOverweight—US$105.00Report
Details

Millicom International Cellular (TIGO) — JPMorgan Chase & Co. upgraded the stock from Neutral to Overweight, with a price target of $105.00.

Report title
Molson Coors BeverageTAPU.S.Wolfe ResearchInitiates————Report
Details

Molson Coors Beverage (TAP) — Wolfe Research initiated coverage with a Peer Perform rating.

Report title
Monster BeverageMNSTU.S.Wolfe ResearchInitiates—Outperform——Report
Details

Monster Beverage (MNST) — Wolfe Research initiated coverage with a Outperform rating.

Report title
MP MaterialsMPU.S.NeedhamResumes—Buy—US$48.00Report
Details

MP Materials (MP) — Needham resumed coverage with a Buy rating and a price target of $48.

Report title
MP MaterialsMPU.S.Needham & Company LLCInitiates—Buy—US$48.00Report
Details

MP Materials (MP) — Needham & Company LLC initiated coverage with a Buy rating and a price target of $48.00.

Report title
Murphy OilMURU.S.Morgan StanleyTarget Up—UnderweightUS$37.00US$39.00Report
Details

Murphy Oil (MUR) — Morgan Stanley raised its price target from $37.00 to $39.00, maintaining an Underweight rating.

Report title
New York TimesNYTU.S.CitigroupDowngradeBuyNeutralUS$85.00US$76.00Report
Details

New York Times (NYT) — Citigroup downgraded the stock from Buy to Neutral and changed its price target from $85.00 to $76.00.

Report title
NIKENKEU.S.BarclaysTarget Down—OverweightUS$45.00US$42.00Report
Details

NIKE (NKE) — Barclays lowered its price target from $45.00 to $42.00, maintaining an Overweight rating.

Report title
NIKENKEU.S.BMO Capital MarketsMaintains—Underperform——Report
Details

NIKE (NKE) — BMO Capital Markets reiterated its Underperform rating.

Report title
NIKENKEU.S.BTIG ResearchMaintains—Buy——Report
Details

NIKE (NKE) — BTIG Research reiterated its Buy rating.

Report title
NIKENKEU.S.JPMorgan Chase & Co.Maintains———US$38.00Report
Details

NIKE (NKE) — JPMorgan Chase & Co. reiterated its price target with a price target of $38.00.

Report title
NIKENKEU.S.Needham & Company LLCMaintains—Hold——Report
Details

NIKE (NKE) — Needham & Company LLC reiterated its Hold rating.

Report title
NucorNUEU.S.Wells Fargo & CompanyTarget Up—OverweightUS$305.00US$308.00Report
Details

Nucor (NUE) — Wells Fargo & Company raised its price target from $305.00 to $308.00, maintaining an Overweight rating.

Report title
NVIDIANVDAU.S.ArgusMaintains—Buy—US$220.00Report
Details

NVIDIA (NVDA) — Argus reiterated its Buy rating with a price target of $220.00.

Report title
NVIDIANVDAU.S.BMO Capital MarketsMaintains—Outperform——Report
Details

NVIDIA (NVDA) — BMO Capital Markets reiterated its Outperform rating.

Report title
NVIDIANVDAU.S.CitigroupMaintains———US$225.00Report
Details

NVIDIA (NVDA) — Citigroup reiterated its price target with a price target of $225.00.

Report title
NVIDIANVDAU.S.DA DavidsonMaintains—Buy—US$200.00Report
Details

NVIDIA (NVDA) — DA Davidson reiterated its Buy rating with a price target of $200.00.

Report title
NVIDIANVDAU.S.HSBCMaintains———US$170.00Report
Details

NVIDIA (NVDA) — HSBC reiterated its price target with a price target of $170.00.

Report title
NVIDIANVDAU.S.Jefferies Financial GroupTarget Down—BuyUS$300.00US$250.00Report
Details

NVIDIA (NVDA) — Jefferies Financial Group reiterated its Buy rating with its price target from $300.00 to $250.00.

Report title
NVIDIANVDAU.S.JPMorgan Chase & Co.Target Up—OverweightUS$215.00US$230.00Report
Details

NVIDIA (NVDA) — JPMorgan Chase & Co. reiterated its Overweight rating with its price target from $215.00 to $230.00.

Report title
NVIDIANVDAU.S.KeyCorpMaintains————Report
Details

NVIDIA (NVDA) — KeyCorp reiterated its Sector Weight rating.

Report title
NVIDIANVDAU.S.Melius ResearchMaintains———US$185.00Report
Details

NVIDIA (NVDA) — Melius Research reiterated its price target with a price target of $185.00.

Report title
NVIDIANVDAU.S.Morgan StanleyTarget Down—OverweightUS$267.00US$260.00Report
Details

NVIDIA (NVDA) — Morgan Stanley lowered its price target from $267.00 to $260.00, maintaining an Overweight rating.

Report title
NVIDIANVDAU.S.Needham & Company LLCMaintains—Buy—US$200.00Report
Details

NVIDIA (NVDA) — Needham & Company LLC reiterated its Buy rating with a price target of $200.00.

Report title
NVIDIANVDAU.S.Piper SandlerTarget Down—OverweightUS$300.00US$230.00Report
Details

NVIDIA (NVDA) — Piper Sandler reiterated its Overweight rating with its price target from $300.00 to $230.00.

Report title
NVIDIANVDAU.S.Royal Bank Of CanadaMaintains—Outperform—US$230.00Report
Details

NVIDIA (NVDA) — Royal Bank Of Canada reiterated its Outperform rating with a price target of $230.00.

Report title
NVIDIANVDAU.S.Summit InsightsDowngradeBuyHold——Report
Details

NVIDIA (NVDA) — Summit Insights downgraded the stock from Buy to Hold.

Report title
NVIDIANVDAU.S.SusquehannaMaintains—Positive——Report
Details

NVIDIA (NVDA) — Susquehanna reiterated its Positive rating.

Report title
NVIDIANVDAU.S.Truist FinancialMaintains———US$174.00Report
Details

NVIDIA (NVDA) — Truist Financial reiterated its price target with a price target of $174.00.

Report title
NVIDIANVDAU.S.WedbushTarget Up—OutperformUS$275.00US$293.00Report
Details

NVIDIA (NVDA) — Wedbush raised its price target from $275.00 to $293.00, maintaining an Outperform rating.

Report title
NVIDIANVDAU.S.Wells Fargo & CompanyTarget Down—OverweightUS$300.00US$250.00Report
Details

NVIDIA (NVDA) — Wells Fargo & Company lowered its price target from $300.00 to $250.00, maintaining an Overweight rating.

Report title
Oaktree Specialty LendingOCSLU.S.Keefe, Bruyette & WoodsTarget Down—Market PerformUS$13.50US$12.50Report
Details

Oaktree Specialty Lending (OCSL) — Keefe, Bruyette & Woods lowered its price target from $13.50 to $12.50, maintaining a Market Perform rating.

Report title
OGE EnergyOGEU.S.JPMorgan Chase & Co.Target Up—OverweightUS$53.00US$56.00Report
Details

OGE Energy (OGE) — JPMorgan Chase & Co. raised its price target from $53.00 to $56.00, maintaining an Overweight rating.

Report title
Once Upon A FarmOFRMU.S.JPMorgan Chase & Co.Target Up—OverweightUS$13.00US$14.00Report
Details

Once Upon A Farm (OFRM) — JPMorgan Chase & Co. raised its price target from $13.00 to $14.00, maintaining an Overweight rating.

Report title
OncocyteIMDXU.S.StephensMaintains—Equal Weight—US$4.00Report
Details

Oncocyte (IMDX) — Stephens reiterated its Equal Weight rating with a price target of $4.00.

Report title
OneWater MarineONEWU.S.KeyCorpMaintains—Overweight——Report
Details

OneWater Marine (ONEW) — KeyCorp reiterated its Overweight rating.

Report title
OperaOPRAU.S.B. Riley FinancialTarget Down—BuyUS$28.00US$27.00Report
Details

Opera (OPRA) — B. Riley Financial lowered its price target from $28.00 to $27.00, maintaining a Buy rating.

Report title
Oric PharmaceuticalsORICU.S.Wells Fargo & CompanyTarget Down—OverweightUS$25.00US$23.00Report
Details

Oric Pharmaceuticals (ORIC) — Wells Fargo & Company lowered its price target from $25.00 to $23.00, maintaining an Overweight rating.

Report title
OrthoPediatricsKIDSU.S.BTIG ResearchTarget Up—BuyUS$30.00US$40.00Report
Details

OrthoPediatrics (KIDS) — BTIG Research raised its price target from $30.00 to $40.00, maintaining a Buy rating.

Report title
OvintivOVVU.S.Morgan StanleyTarget Up—Equal WeightUS$71.00US$72.00Report
Details

Ovintiv (OVV) — Morgan Stanley raised its price target from $71.00 to $72.00, maintaining an Equal Weight rating.

Report title
PaysafePSFEU.S.SusquehannaTarget Down—NeutralUS$7.00US$3.50Report
Details

Paysafe (PSFE) — Susquehanna lowered its price target from $7.00 to $3.50, maintaining a Neutral rating.

Report title
PepsiCoPEPU.S.Wolfe ResearchInitiates————Report
Details

PepsiCo (PEP) — Wolfe Research initiated coverage with a Peer Perform rating.

Report title
Petroleo Brasileiro S.A. - PetrobrasPBRU.S.JPMorgan Chase & Co.Target Down—OverweightUS$24.00US$23.50Report
Details

Petroleo Brasileiro S.A. - Petrobras (PBR) — JPMorgan Chase & Co. lowered its price target from $24.00 to $23.50, maintaining an Overweight rating.

Report title
Phathom PharmaceuticalsPHATU.S.BarclaysTarget Down—OverweightUS$14.00US$10.00Report
Details

Phathom Pharmaceuticals (PHAT) — Barclays lowered its price target from $14.00 to $10.00, maintaining an Overweight rating.

Report title
Pilgrim's PridePPCU.S.UBS GroupTarget Up—NeutralUS$28.00US$31.00Report
Details

Pilgrim's Pride (PPC) — UBS Group raised its price target from $28.00 to $31.00, maintaining a Neutral rating.

Report title
Planet FitnessPLNTU.S.UBS GroupTarget Up—BuyUS$80.00US$83.00Report
Details

Planet Fitness (PLNT) — UBS Group raised its price target from $80.00 to $83.00, maintaining a Buy rating.

Report title
PMET Resources Inc.PMET:CACanadaNational BankTarget Up—OutperformC$7.75C$8.50Report
Details

PMET Resources Inc. (PMET:CA) — National Bank raised its price target from C$7.75 to C$8.50, maintaining an Outperform rating.

Report title
Portland General ElectricPORU.S.JPMorgan Chase & Co.Target Down—NeutralUS$50.00US$48.00Report
Details

Portland General Electric (POR) — JPMorgan Chase & Co. lowered its price target from $50.00 to $48.00, maintaining a Neutral rating.

Report title
Portman Ridge FinanceBCICU.S.Keefe, Bruyette & WoodsTarget Down—Market PerformUS$7.50US$6.50Report
Details

Portman Ridge Finance (BCIC) — Keefe, Bruyette & Woods lowered its price target from $7.50 to $6.50, maintaining a Market Perform rating.

Report title
Prelude TherapeuticsPRLDU.S.HC WainwrightMaintains—Buy—US$8.00Report
Details

Prelude Therapeutics (PRLD) — HC Wainwright reiterated its Buy rating with a price target of $8.00.

Report title
Procter & GamblePGU.S.Wells Fargo & CompanyTarget Up—OverweightUS$180.00US$188.00Report
Details

Procter & Gamble (PG) — Wells Fargo & Company raised its price target from $180.00 to $188.00, maintaining an Overweight rating.

Report title
PulmonxLUNGU.S.Loop CapitalMaintains———US$7.00Report
Details

Pulmonx (LUNG) — Loop Capital reiterated its price target with a price target of $7.00.

Report title
QualcommQCOMU.S.Robert W. BairdTarget Down—OutperformUS$320.00US$300.00Report
Details

Qualcomm (QCOM) — Robert W. Baird lowered its price target from $320.00 to $300.00, maintaining an Outperform rating.

Report title
Range ResourcesRRCU.S.Morgan StanleyTarget Up—Equal WeightUS$45.00US$50.00Report
Details

Range Resources (RRC) — Morgan Stanley raised its price target from $45.00 to $50.00, maintaining an Equal Weight rating.

Report title
Recursion PharmaceuticalsRXRXU.S.Morgan StanleyTarget Down—Equal WeightUS$5.90US$5.60Report
Details

Recursion Pharmaceuticals (RXRX) — Morgan Stanley lowered its price target from $5.90 to $5.60, maintaining an Equal Weight rating.

Report title
Rein TherapeuticsRNTXU.S.HC WainwrightMaintains—Buy——Report
Details

Rein Therapeutics (RNTX) — HC Wainwright reiterated its Buy rating.

Report title
RelianceRSU.S.Wells Fargo & CompanyTarget Up—Equal WeightUS$420.00US$452.00Report
Details

Reliance (RS) — Wells Fargo & Company raised its price target from $420.00 to $452.00, maintaining an Equal Weight rating.

Report title
RelxRELXU.S.Erste Group BankInitiates—Buy——Report
Details

Relx (RELX) — Erste Group Bank initiated coverage with a Buy rating.

Report title
Royalty PharmaRPRXU.S.TD CowenTarget Up—BuyUS$68.00US$80.00Report
Details

Royalty Pharma (RPRX) — TD Cowen raised its price target from $68.00 to $80.00, maintaining a Buy rating.

Report title
SabreSABRU.S.Cantor FitzgeraldMaintains—Neutral—US$2.00Report
Details

Sabre (SABR) — Cantor Fitzgerald reiterated its Neutral rating with a price target of $2.00.

Report title
SalesforceCRMU.S.BTIG ResearchTarget Down—BuyUS$300.00US$250.00Report
Details

Salesforce (CRM) — BTIG Research lowered its price target from $300.00 to $250.00, maintaining a Buy rating.

Report title
Savaria Corp.SIS:CACanadaTD SecuritiesMaintains—Buy—C$38.00Report
Details

Savaria Corp. (SIS:CA) — TD Securities maintained a Buy rating with a price target of C$38.00.

Report title
SecuritizeSECZU.S.B. Riley FinancialInitiates—Buy—US$14.00Report
Details

Securitize (SECZ) — B. Riley Financial initiated coverage with a Buy rating and a price target of $14.00.

Report title
SecuritizeSECZU.S.B. Riley SecuritiesInitiates—Buy—US$14.00Report
Details

Securitize (SECZ) — B. Riley Securities initiated coverage with a Buy rating and a price target of $14.

Report title
ServiceTitanTTANU.S.Piper SandlerMaintains—Overweight—US$110.00Report
Details

ServiceTitan (TTAN) — Piper Sandler reiterated its Overweight rating with a price target of $110.00.

Report title
Sherwin-WilliamsSHWU.S.ArgusMaintains—Buy—US$380.00Report
Details

Sherwin-Williams (SHW) — Argus reiterated its Buy rating with a price target of $380.00.

Report title
Sienna Senior Living Inc.SIA:CACanadaScotiabankMaintains—Sector Outperform—C$26.00Report
Details

Sienna Senior Living Inc. (SIA:CA) — Scotiabank maintained a Sector Outperform rating with a price target of C$26.00.

Report title
SimilarwebSMWBU.S.BarclaysTarget Up—OverweightUS$11.00US$13.00Report
Details

Similarweb (SMWB) — Barclays raised its price target from $11.00 to $13.00, maintaining an Overweight rating.

Report title
SinclairSBGIU.S.GuggenheimTarget Up—BuyUS$19.00US$20.00Report
Details

Sinclair (SBGI) — Guggenheim raised its price target from $19.00 to $20.00, maintaining a Buy rating.

Report title
SKYX PlatformsSKYXU.S.Subscribe to MarketBeat All Access to unlock brokerage rankingsTarget Down—BuyUS$2.50US$2.00Report
Details

SKYX Platforms (SKYX) — Subscribe to MarketBeat All Access to unlock brokerage rankings lowered its price target from $2.50 to $2.00, maintaining a Buy rating.

Report title
SLR InvestmentSLRCU.S.Keefe, Bruyette & WoodsTarget Down—Market PerformUS$13.50US$13.00Report
Details

SLR Investment (SLRC) — Keefe, Bruyette & Woods lowered its price target from $13.50 to $13.00, maintaining a Market Perform rating.

Report title
SnowflakeSNOWU.S.UBS GroupTarget Down—BuyUS$500.00US$450.00Report
Details

Snowflake (SNOW) — UBS Group lowered its price target from $500.00 to $450.00, maintaining a Buy rating.

Report title
Snowline Gold Corp.SGD:CACanadaCIBCMaintains—Outperform—C$27.00Report
Details

Snowline Gold Corp. (SGD:CA) — CIBC maintained an Outperform rating with a price target of C$27.00.

Report title
SOLV EnergyMWHU.S.UBSUpgradeNeutralBuy—US$37.00Report
Details

SOLV Energy (MWH) — UBS upgraded the stock from Neutral to Buy, with a price target of $37.

Report title
SOLV EnergyMWHU.S.UBS GroupUpgradeNeutralBuyUS$50.00US$37.00Report
Details

SOLV Energy (MWH) — UBS Group upgraded the stock from Neutral to Buy and changed its price target from $50.00 to $37.00.

Report title
SpireSRU.S.MizuhoTarget Up—OutperformUS$93.00US$96.00Report
Details

Spire (SR) — Mizuho raised its price target from $93.00 to $96.00, maintaining an Outperform rating.

Report title
Steel DynamicsSTLDU.S.Wells Fargo & CompanyTarget Up—OverweightUS$271.00US$285.00Report
Details

Steel Dynamics (STLD) — Wells Fargo & Company raised its price target from $271.00 to $285.00, maintaining an Overweight rating.

Report title
StrykerSYKU.S.BTIG ResearchTarget Up—BuyUS$304.00US$345.00Report
Details

Stryker (SYK) — BTIG Research raised its price target from $304.00 to $345.00, maintaining a Buy rating.

Report title
Summit TherapeuticsSMMTU.S.BernsteinDowngradeMarket PerformUnderperform—US$8.30Report
Details

Summit Therapeutics (SMMT) — Bernstein downgraded the stock from Market Perform to Underperform, with a price target of $8.30.

Report title
Summit TherapeuticsSMMTU.S.Sanford C. BernsteinDowngradeMarket PerformUnderperformUS$11.90US$8.30Report
Details

Summit Therapeutics (SMMT) — Sanford C. Bernstein downgraded the stock from Market Perform to Underperform and changed its price target from $11.90 to $8.30.

Report title
Superior Plus Corp.SPB:CACanadaStifel NicolausTarget Down—BuyC$10.00C$8.50Report
Details

Superior Plus Corp. (SPB:CA) — Stifel Nicolaus lowered its price target from C$10.00 to C$8.50, maintaining a Buy rating.

Report title
Tandem Diabetes CareTNDMU.S.Lake Street CapitalInitiates—Buy——Report
Details

Tandem Diabetes Care (TNDM) — Lake Street Capital initiated coverage with a Buy rating.

Report title
Tandem Diabetes CareTNDMU.S.Piper SandlerInitiates—Neutral——Report
Details

Tandem Diabetes Care (TNDM) — Piper Sandler initiated coverage with a Neutral ? Overweight rating.

Report title
Tandem Diabetes CareTNDMU.S.Raymond James FinancialUpgradeMarket PerformStrong-Buy——Report
Details

Tandem Diabetes Care (TNDM) — Raymond James Financial upgraded the stock from Market Perform to Strong-Buy.

Report title
Tandem Diabetes CareTNDMU.S.Stifel NicolausUpgradeHoldBuyUS$22.00US$26.00Report
Details

Tandem Diabetes Care (TNDM) — Stifel Nicolaus upgraded the stock from Hold to Buy and changed its price target from $22.00 to $26.00.

Report title
Tandem Diabetes CareTNDMU.S.UBS GroupUpgradeNeutralBuy——Report
Details

Tandem Diabetes Care (TNDM) — UBS Group upgraded the stock from Neutral to Buy.

Report title
Tencent Music Entertainment GroupTMEU.S.MizuhoTarget Down—OutperformUS$15.00US$14.00Report
Details

Tencent Music Entertainment Group (TME) — Mizuho lowered its price target from $15.00 to $14.00, maintaining an Outperform rating.

Report title
Transat A.T. Inc.TRZ:CACanadaCIBCTarget Down—UnderperformC$1.75C$1.50Report
Details

Transat A.T. Inc. (TRZ:CA) — CIBC lowered its price target from C$1.75 to C$1.50, maintaining an Underperform rating.

Report title
Transat A.T. Inc.TRZ:CACanadaNational BankTarget Down—UnderperformC$1.50C$1.15Report
Details

Transat A.T. Inc. (TRZ:CA) — National Bank lowered its price target from C$1.50 to C$1.15, maintaining an Underperform rating.

Report title
Tyler TechnologiesTYLU.S.TD CowenTarget Up—BuyUS$450.00US$475.00Report
Details

Tyler Technologies (TYL) — TD Cowen raised its price target from $450.00 to $475.00, maintaining a Buy rating.

Report title
Tyler TechnologiesTYLU.S.Truist FinancialTarget Up—BuyUS$440.00US$500.00Report
Details

Tyler Technologies (TYL) — Truist Financial reiterated its Buy rating with its price target from $440.00 to $500.00.

Report title
Tyson FoodsTSNU.S.Bank of AmericaTarget Up—NeutralUS$56.00US$65.00Report
Details

Tyson Foods (TSN) — Bank of America raised its price target from $56.00 to $65.00, maintaining a Neutral rating.

Report title
uniQureQUREU.S.HC WainwrightTarget Down—BuyUS$80.00US$65.00Report
Details

uniQure (QURE) — HC Wainwright lowered its price target from $80.00 to $65.00, maintaining a Buy rating.

Report title
United States AntimonyUAMYU.S.B. Riley FinancialTarget Down—BuyUS$10.00US$6.00Report
Details

United States Antimony (UAMY) — B. Riley Financial lowered its price target from $10.00 to $6.00, maintaining a Buy rating.

Report title
VericelVCELU.S.BTIG ResearchMaintains—Neutral——Report
Details

Vericel (VCEL) — BTIG Research reiterated its Neutral rating.

Report title
VeritoneVERIU.S.HC WainwrightInitiates—Buy—US$2.00Report
Details

Veritone (VERI) — HC Wainwright initiated coverage with a Buy rating and a price target of $2.00.

Report title
VikingVIKU.S.BarclaysTarget Up—OverweightUS$102.00US$111.00Report
Details

Viking (VIK) — Barclays raised its price target from $102.00 to $111.00, maintaining an Overweight rating.

Report title
VikingVIKU.S.JPMorgan Chase & Co.Target Down—OverweightUS$131.00US$122.00Report
Details

Viking (VIK) — JPMorgan Chase & Co. lowered its price target from $131.00 to $122.00, maintaining an Overweight rating.

Report title
VikingVIKU.S.Morgan StanleyTarget Up—Equal WeightUS$92.00US$100.00Report
Details

Viking (VIK) — Morgan Stanley raised its price target from $92.00 to $100.00, maintaining an Equal Weight rating.

Report title
VikingVIKU.S.Wells Fargo & CompanyTarget Up—OverweightUS$118.00US$120.00Report
Details

Viking (VIK) — Wells Fargo & Company raised its price target from $118.00 to $120.00, maintaining an Overweight rating.

Report title
Vista EnergyVISTU.S.UBS GroupTarget Up—BuyUS$80.00US$100.00Report
Details

Vista Energy (VIST) — UBS Group raised its price target from $80.00 to $100.00, maintaining a Buy rating.

Report title
Vital Infrastructure Property TrustVITL.UN:CACanadaRBCTarget Down—Sector PerformC$6.00C$5.50Report
Details

Vital Infrastructure Property Trust (VITL.UN:CA) — RBC lowered its price target from C$6.00 to C$5.50, maintaining a Sector Perform rating.

Report title
VolitionRxVNRXU.S.Freedom BrokerDowngradeBuyHold——Report
Details

VolitionRx (VNRX) — Freedom Broker downgraded the stock from Buy to Hold.

Report title
Walt DisneyDISU.S.Bank of AmericaTarget Up—BuyUS$125.00US$135.00Report
Details

Walt Disney (DIS) — Bank of America raised its price target from $125.00 to $135.00, maintaining a Buy rating.

Report title
Walt DisneyDISU.S.BarclaysTarget Up—OverweightUS$115.00US$135.00Report
Details

Walt Disney (DIS) — Barclays raised its price target from $115.00 to $135.00, maintaining an Overweight rating.

Report title
Walt DisneyDISU.S.GuggenheimTarget Up—BuyUS$120.00US$135.00Report
Details

Walt Disney (DIS) — Guggenheim raised its price target from $120.00 to $135.00, maintaining a Buy rating.

Report title
Walt DisneyDISU.S.JPMorgan Chase & Co.Target Up—OverweightUS$137.00US$140.00Report
Details

Walt Disney (DIS) — JPMorgan Chase & Co. raised its price target from $137.00 to $140.00, maintaining an Overweight rating.

Report title
Walt DisneyDISU.S.Needham & Company LLCTarget Up—BuyUS$125.00US$135.00Report
Details

Walt Disney (DIS) — Needham & Company LLC raised its price target from $125.00 to $135.00, maintaining a Buy rating.

Report title
Walt DisneyDISU.S.Raymond James FinancialMaintains—Outperform—US$133.00Report
Details

Walt Disney (DIS) — Raymond James Financial reiterated its Outperform rating with a price target of $133.00.

Report title
Walt DisneyDISU.S.Rosenblatt SecuritiesTarget Up—BuyUS$126.00US$141.00Report
Details

Walt Disney (DIS) — Rosenblatt Securities raised its price target from $126.00 to $141.00, maintaining a Buy rating.

Report title
Walt DisneyDISU.S.Wells Fargo & CompanyTarget Up—OverweightUS$132.00US$140.00Report
Details

Walt Disney (DIS) — Wells Fargo & Company raised its price target from $132.00 to $140.00, maintaining an Overweight rating.

Report title
XPENGXPEVU.S.BarclaysTarget Down—UnderweightUS$14.00US$12.00Report
Details

XPENG (XPEV) — Barclays lowered its price target from $14.00 to $12.00, maintaining an Underweight rating.

Report title
Xtract One Technologies Inc.XTRA:CACanadaVentum FinancialMaintains—Buy—C$1.15Report
Details

Xtract One Technologies Inc. (XTRA:CA) — Ventum Financial maintained a Buy rating with a price target of C$1.15.

Report title
York Space SystemsYSSU.S.BarclaysTarget Down—Equal WeightUS$11.00US$5.00Report
Details

York Space Systems (YSS) — Barclays lowered its price target from $11.00 to $5.00, maintaining an Equal Weight rating.

Report title
Zoom CommunicationsZMU.S.BTIG ResearchTarget Down—BuyUS$125.00US$115.00Report
Details

Zoom Communications (ZM) — BTIG Research lowered its price target from $125.00 to $115.00, maintaining a Buy rating.

Report title
Zoom CommunicationsZMU.S.Rosenblatt SecuritiesMaintains—Buy—US$130.00Report
Details

Zoom Communications (ZM) — Rosenblatt Securities reiterated its Buy rating with a price target of $130.00.

Report title
ZoomInfo TechnologiesGTMU.S.Morgan StanleyTarget Down—Equal WeightUS$5.00US$4.00Report
Details

ZoomInfo Technologies (GTM) — Morgan Stanley lowered its price target from $5.00 to $4.00, maintaining an Equal Weight rating.

Report title

Report date: 2026-11-18 · Dates use America/New_York. Automatically reflects published daily analyst reports. Coverage is limited to recognizable entries in those reports; missing fields appear as —. Targets retain the currency stated in the report. Exact duplicate calls are removed; different analysts and materially different updates remain separate. Summary counts cover the selected date before filtering.

Source reports for this date

American Analyst Ratings Updates — November 18, 2026

Canadian Analyst Ratings Updates — November 18, 2026

Available date history comes from the latest 300 matching analyst articles. Analyst ratings and targets are estimates, not guaranteed outcomes.